Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus®
|ClinicalTrials.gov Identifier: NCT01288170|
Recruitment Status : Unknown
Verified February 2011 by Erempharma.
Recruitment status was: Recruiting
First Posted : February 2, 2011
Last Update Posted : February 2, 2011
Cystic fibrosis (CF) is a genetic disease characterized by mutations in CFTR (Cystic Fibrosis Transmembrane conductance Regulator) gene. Mortality and morbidity are mostly related to the respiratory affection which appears early in neonates.
The constant improvement in symptomatic treatments and care strategies allowed CF patients' life expectancy to be increased over the last decades.
Vital prognostic is related to bronchopulmonary infections. 39% of CF patients under 18 years old and 70% of adult CF patients are chronically infected by Pseudomonas aeruginosa.
Elevated concentrations of tobramycin in broncho secretions, about 1000 times the MIC, is obtained by inhaled administration of tobramycin and is active against in vitro resistant Pseudomonas aeruginosa.
Study hypotheses :
Regarding literature data and in vitro studies, the administration of Nebcinal® 150mg/3ml administered twice a day by Aeroneb® Idehaler® pocket® would deliver the same quantity of antibiotic in lung and plasma as Tobi® 300mg/5ml administered twice a day by Pari® LC Plus® in children and adult patients with CF.
Primary objective :
To compare plasma concentrations after inhalation of Nebcinal® 150mg/3ml administered by Aeroneb® Idehaler pocket® and Tobi® 300 mg/5ml administered by Pari LC Plus®
|Condition or disease||Intervention/treatment|
|Cystic Fibrosis||Drug: Nebcinal Tobi Drug: Tobi Nebcinal|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||12 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||Pharmacokinetic Bioequivalence Study of Nebcinal® 150mg/3ml Administered by Aeroneb® Idehaler® Versus Tobi® 300mg/5ml Administered by Pari LC Plus®|
|Study Start Date :||February 2010|
|Estimated Primary Completion Date :||July 2010|
U.S. FDA Resources
|Drug: Nebcinal Tobi|
|Drug: Tobi Nebcinal|
- plasma Area under the curve from 0 to 8 hours of tobramycine after administration of the drug
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01288170
|Contact: Behrouz Kassaï||0427857732 ext firstname.lastname@example.org|
|Centre de ressources et de compétences pour la mucovisidose, enfants||Recruiting|
|Bron, France, 69500|
|Principal Investigator: Gabriel Bellon, Professor|
|Centre de ressources et de compétences pour la mucovisidose, adultes||Not yet recruiting|
|Pierre-Bénite, France, 69495|
|Sub-Investigator: Isabelle Durieu, Professor|